POSSIBLE PROGRESSION OF SUB ACUTE LUPUS ERYTHEMATOSUS - CASE REPORT

Authors

  • Daciana Elena BRANISTEANU University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi
  • Andreea LABONTU “Sf. Spiridon” Emergency Clinical Hospital, Iaşi
  • Delia CIOBANU “Sf. Spiridon” Emergency Clinical Hospital, Iaşi
  • Gabriela STOLERIU University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi
  • D. BRANISTEANU “Sf. Spiridon” Emergency Clinical Hospital, Iaşi
  • A. OANTA Transilvania University, Faculty of Medicine - Brașov

Abstract

Subacute lupus erythematosus (SLE) is a specific form of lupus erythematosus characterized by prevalently cutaneous manifestations usually with a good prognosis. It is more common in patients aged 15 to 70 years, and there is a female predilection. This form accounts for 10% of all lupus erythematosus cases. We present the case of a 57-year-old male patient diagnosed at age 35 with chronic psoriasiform subacute lupus erythematosus, pathologically confirmed at the Iaşi Dermatology Clinic. At the age of 54 years he had multiple ischemic strokes, followed by deterioration of general status, and at 56 years deep vein thrombosis in the right leg. The patient presented the erythematous-squamous lesions specific to psoriasiform SLE localized both on the upper third of the body and knees and associated with submucosal lesions of the lower lip, oral mucosa and appendages. The patient also presented hypo- and hyperpigmentated atrophic scar-like lesions. Laboratory tests performed during the last two admissions showed the presence of anti-ds DNA and antiphospholipid antibodies, inflammatory syndrome, and nitrogen retention syndrome. Treatment consisted of systemic and local dermatocorticoids and associated medication, emollient lotions and creams with SPF 50+, with slowly favorable progression. The peculiarity of the case lies in the chronic progression without significant systemic involvement for 19 years, and then in 2 years the antiphospholipid antibody syndrome and a shift to systemic lupus erythematosus to occur.

Author Biographies

  • Daciana Elena BRANISTEANU, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty  of  Medicine
    Discipline of Dermatology

  • Andreea LABONTU, “Sf. Spiridon” Emergency Clinical Hospital, Iaşi

    Department of Dermatology

  • Delia CIOBANU, “Sf. Spiridon” Emergency Clinical Hospital, Iaşi

    Department of Pathology

  • Gabriela STOLERIU, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty  of  Medicine
    Discipline of Dermatology

  • D. BRANISTEANU, “Sf. Spiridon” Emergency Clinical Hospital, Iaşi

    Discipline of Ophthalmology

  • A. OANTA, Transilvania University, Faculty of Medicine - Brașov

    Department of Dermatology

References

1. Rook AJ, Wilkinson DS, Ebling FJ. et al. Textbook of Dermatology, Seventh edition, Blackwell Pub-lishing, USA, 2004.
2. Fitzpatrik TB. et al. Dermatology in General Medicine, Seventh Edition, USA, 2008.
3. Fonseca E. et al. Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus. Lupus. 1992; 4: 265-268.
4. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology, Text with Continually Updated Online Reference, Ed. Elsevier, USA, 2008.
5. Lockshin MD. Pregnancy and antiphospholipid syndrome. Am J Reprod Imm. 2013; 69: 585.
6. Donadini MP, et al. Antiphospholipid syndrome: A challenging hypercoagulable state with systemic manifestations. Hematol Oncol Clin N Am. 2010; 24: 669.
7. Saurat JH. et al. Dermatologie et infections sexuellement transmissibles, 5e Edition, France, Elsevier Masson, 2009.
8. Joly P. et al. Dermatologie- connaissances et practique, France, Elsevier Masson, 2008.
9. Petrescu Z. et al. Dermatology and sexually transmitted infections, Junimea, Publishing, Iasi, Romania, 2008.
10. Boggs W. Progression from Cutaneous to Systemic Lupus Erythematosus may not involve systemic symptoms. JAMA Dermatol. 2014; 150 (3): 291-296.

Additional Files

Published

2018-05-07

Issue

Section

INTERNAL MEDICINE - PEDIATRICS